IP Library › Granted Patent US 12,636,327
Granted Patent B2
US 12,636,327 · App. 18/001,243 · Granted May 26, 2026

Probiotic composition for treatment of oral

Inventors: Erik Brandsborg (Holbæk, DK); Lasse Sommer Mikkelsen (Frederiksværk, DK)
Assignee: ADM Denmark A/S
A61K35/747A61P31/10C12N1/205C12R2001/225
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,636,327
App. No.
18/001,243
Granted
May 26, 2026
Kind
B2
Abstract

The present invention relates to a Lactobacillus rhamnosus strain. In particular, the present invention relates to a composition comprising a Lactobacillus rhamnosus optionally in combination with a further lactobacilli and the use of the same in the treatment, prevention or alleviation of candidiasis.

Claims (18)

1 . A Lactobacillus rhamnosus strain ERB 36 having accession number DSM 32992, wherein said strain is in a lyophilized, spray dried, vacuum dried or microencapsulated form or any combination thereof.

2 . A culture broth comprising Lactobacillus rhamnosus strain ERB 36 having accession number DSM 32992, wherein said broth is in a lyophilized, spray dried, vacuum dried or microencapsulated form or any combination thereof.

3 . The culture broth according to claim 2 , further comprising at least one lactobacilli sp. selected from the group consisting of Lactobacillus rhamnosus strain ERB18 having accession number DSM 32991, Lactobacillus rhamnosus strain PB01 having accession number DSM 14870 and Lactobacillus curvatus EB10 having accession number DSM 32307.

4 . A composition comprising Lactobacillus rhamnosus strain ERB 36 having accession number DSM 32992, wherein said strain is in a lyophilized, spray dried, vacuum dried or microencapsulated form or any combination thereof, wherein said composition is in the form of a tablet, a capsule, an effervescent tablet, an effervescent powder, a microencapsulated product, a gel or a cream.

5 . The composition according to claim 4 , comprising at least one further lactobacilli sp. selected from the group consisting of Lactobacillus rhamnosus strain ERB18 having accession number DSM 32991, Lactobacillus rhamnosus strain PB01 having accession number DSM 14870 and Lactobacillus curvatus EB10 having accession number DSM 32307.

6 . The composition according to claim 4 , wherein said composition comprises from 10 5 to 10 13 CFU of lactobacilli per gram of said composition.

7 . The composition according to claim 4 , further comprising a bulking agent, a binder, a glazing agent, a sweetener or a flavour.

8 . A method comprising administering to a subject in need of a probiotic:

a) Lactobacillus rhamnosus strain ERB 36 having accession number DSM 32992, wherein said strain is in a lyophilized, spray dried, vacuum dried or microencapsulated form or any combination thereof; or,

b) the composition of claim 4 .

9 . A method of treating or alleviating candidiasis in a subject, comprising administering Lactobacillus rhamnosus strain ERB 36 having accession number DSM 32992, wherein said strain is in a lyophilized, spray dried, vacuum dried or microencapsulated form or any combination thereof to a subject in need thereof.

10 . The method according to claim 9 , wherein said candidiasis is oral or vaginal candidiasis.

11 . The method of claim 9 , wherein said candidiasis is caused by a Candida spp. selected from the group consisting of Candida glabrata, Candida krusei, Candida tropicalis, Candida dubliniensis, Candida parapsilosis , and Candida albicans.

12 . A container containing Lactobacillus rhamnosus strain ERB 36 having accession number DSM 32992, wherein said strain is in a lyophilized, spray dried, vacuum dried or microencapsulated form or any combination thereof, or the composition according to claim 4 .

13 . The container according to claim 12 , wherein said container is a blister pack, stick, bag, pouch, sachet, or capsule.

14 . A method of treating or alleviating candidiasis in a subject, comprising administering the composition of claim 4 to a subject in need thereof.

15 . The composition according to claim 4 , comprising at least one further lactobacilli sp. selected from the group consisting of Lactobacillus rhamnosus strain ERB18 having accession number DSM 32991, Lactobacillus rhamnosus strain PB01 having accession number DSM 14870 and Lactobacillus curvatus EB10 having accession number DSM 32307.

16 . A method of treating or alleviating candidiasis in a subject, comprising administering the composition of claim 15 to a subject in need thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2024
From: BRANDSBORG, ERIK; MIKKELSEN, LASSE SOMMER
To: DEERLAND PROBIOTICS & ENZYMES A/S
Reel/Frame 068229/0064 →
CHANGE OF NAME Recorded Aug 8, 2024
From: DEERLAND PROBIOTICS & ENZYMES A/S
To: ADM DENMARK A/S
Reel/Frame 068519/0288 →
Priority Claims (1)
EP 20179563 · Jun 11, 2020 · regional
Continuity (1)
Related Publication 20230302066A1 · Sep 28, 2023
References Cited (5)
WO WO2017001440A1 · 2017 [cited by applicant]
International Search Report mailed Sep. 9, 2014 in International Application No. PCT/EP2021/065710. [cited by applicant]
Martinez et al., “Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic [cited by applicant]
Jørgensen et al., “ [cited by applicant]
Zangl et al., “The role of [cited by applicant]